NICHI-IKO PHARMACEUTICAL Aktie

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2021, NICHI-IKO PHARMACEUTICAL Aktie has already paid €0.15 in dividends. The last payout was in December 2021.

Financials

In the last year, NICHI-IKO PHARMACEUTICAL Aktie had revenue of €117.14B and net profit of €4.51B

(EUR)	2023	YoY
Revenue	117.14B	8,719.44%
Gross profit	23.08B	78,360.97%
Net profit	4.51B	675.88%
EBITDA	14.73B	2,210.92%

Fundamentals

Metric	Value
Market capitalization	€13.85M
Number of shares	70.43M
Dividends	No
Beta	-0.66
P/E ratio	0.27
PEG ratio	0.00
P/B ratio	0.02
P/S ratio	0.00

Company profile

Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, imports, and distributes various pharmaceutical products. The company operates through two segments, Sagent Group and Nichi-Iko Group. It primarily focuses on the production of generic drugs. The company offers antidiabetic agents, antacids, antireflux agents, beta-blocker, hypnotic and sedative, angiotensin ? antagonist, angiotensin ? antagonist/diuretic combination, dyslipidaemic agent, and calcium antagonist products. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems, and others. In addition, the company engages in the packaging design business. Further, it exports its products. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was incorporated in 1947 and is headquartered in Toyama, Japan.